Attention AACR Annual Meeting 2018 Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 33 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 30 31 32 33 presentations: 1 to 25 of 824
Autophagy overview and roles in tumor cell death
Andrew M. Thorburn
Univ. of Colorado Denver, Aurora, CO, United States
from AACR Annual Meeting 2018 on April 14, 2018 10:15 AM-12:15 PM
Autophagy in tumor progression to metastasis
Kay F Macleod
Univ. of Chicago Ben May Dept. for Cancer Res., Chicago, IL, United States
from AACR Annual Meeting 2018 on April 14, 2018 10:15 AM-12:15 PM
Autophagy in the tumor immune response
Lorenzo Galluzzi
Weill Cornell Medical College, New York, NY, United States
from AACR Annual Meeting 2018 on April 14, 2018 10:15 AM-12:15 PM
Targeting autophagy in the clinic and next generation autophagy drugs
Ravi K. Amaravadi
Univ. of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2018 on April 14, 2018 10:15 AM-12:15 PM
Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase II PURE-01 study
Andrea Necchi
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Discussant
James L Gulley
National Cancer Inst., Bethesda, MD, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Front-line therapy of DIPG using the IDO pathway inhibitor indoximod in combination with radiation and chemotherapy
Theodore S Johnson
Georgia Cancer Center, Augusta University, Augusta, GA, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Discussant
Derek A Wainwright
Northwestern University Feinberg School of Medicine, Brookfiled, IL, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
FLT3 ligand (CDX-301) and stereotactic radiotherapy for advanced non-small cell lung cancer
Nitin Ohri
Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Discussant
Silvia C Formenti
Weill Cornell Medical College, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Intraperitoneal radioimmunotherapy for desmoplastic small round cell tumor: Results of a phase I study (NCT01099644)
Shakeel Modak
MSKCC, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Discussant
Kunle Odunsi
Roswell Park Cancer Inst., Buffalo, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 12:45 PM-2:50 PM
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors
Vivek Subbiah
Department of Investigational Cancer Therapeutics The University of MD Anderson Cancer Texas, Houston, TX, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Alexander E Drilon
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
Alice T. Shaw
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Christine M. Lovly
Vanderbilt Univ. School of Medicine, Nashville, TN, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE"
Patrick Schoffski
Catholic Univ. of Leuven - Leuven Cancer Inst., Leuven, Belgium
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Benjamin J Solomon
Peter MacCallum Cancer Ctr., Melbourne, Australia
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
Komal Jhaveri
Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Discussant
Timothy A Yap
The University of Texas MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 15, 2018 3:00 PM-5:05 PM
Overview of thyroid cancer: Epidemiology to state-of art standard of care
Steven I. Sherman
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Cancer genomics: Well to poorly differentiated thyroid carcinoma
James A Fagin
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Discovering targeted therapies of thyroid cancer using drosophila models
Ross L Cagan
Mount Sinai School of Medicine, New York, NY, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
BRAF-targetedtherapy and mechanisms of resistance in thyroid cancer clinical trials
Manisha H Shah
Ohio State Univ. Comp. Cancer Ctr., Columbus, OH, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
Emerging novel RET-Targeted therapy in thyroid cancer
Lori J Wirth
Massachusetts General Hospital, Boston, MA, United States
from AACR Annual Meeting 2018 on April 14, 2018 8:00 AM-10:00 AM
<< first | < prev page: of 33 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 30 31 32 33 presentations: 1 to 25 of 824